http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
김용범,박노현,이철민,김재원,송용상,강순범,이효표,노주원,이택상 대한부인종양 콜포스코피학회 1999 Journal of Gynecologic Oncology Vol.10 No.2
Backgrouad & Aims: Cyclophosphamide, adriamycin and cisplatin(CAP) combination chemo- therapy improved the response rate in the treatment of advanced epithelial ovarian cancer, and it has been the gold standard. However, adriamycin is a rather toxic drug, and there is still confusion concerning the choice of adriamycin to be included in optimal regimen. The present study was designed to compare the activity and toxicity of combination regimens in advanced epithelial ovarian cancer between CAP and CTP which substitutes adriamycin with pirarubicin(THP-adriamycin). Patients and Methods: From March 1995 to December 1997, 47 patients with FIGO stage III-IV epithelial ovarian cancer who were diagnosed after initial cytoreductive surgery were divided into two groups at random: (1) The case group were treated with CTP(500/40/50 ㎎/㎡) as a first line chemotherapy. (2) The control group were treated with CAP(500/50/50 ㎎/㎡) as that of case group. Clinical characteristics, response rates and toxicities according to Gynecologic Oncology Group criteria were compared between those treated with CAP and CTP respectively. Results: Forty one patients out of 47 were evaluable and the number of patients in case and control group was 22 and 19 respectively. There was no significant differences in patient characteristics such as age, stage, histologic type between two groups. Clinical complete response rate was 50.0%(11/22) in patients treated with CTP regimen and 47.4%(9/19) with CAP regimen and there was no significant difference between two groups.
난소암에서 HER-2/neu 유전자 증폭과 Platinum-based 항암화학요법 반응도와의 연관성에 관한 연구
김용범,박노현,이철민,김재원,송용상,강순범,이효표,노주원 대한부인종양 콜포스코피학회 1999 Journal of Gynecologic Oncology Vol.10 No.2
Background: The HER-2/neu proto-oncogene (also known as c-ErbB-2) encodes a 185 kD transmembrane glycoprotein with intrinsic tyrosine kinase activity. Many studies revealed the correlation between the aberrant overexpression of HER-2/neu oncogene and poor prognosis of the malignant tumors such as breast, stomach, colon, lung cancers. But the significance of HER-2/neu oncogene overexpression as a prognostic factor in ovarian cancer remains controversial. Objective: The aims of this study were to assess the prevalence of HER-2/neu oncogene amplification by polymerase chain reaction(PCR) and to evaluate the prognostic significance of HER-2/neu oncogene overexpression in terms of chemo-responsiveness and survival rate. Materials and methods: This study included 32 patients with advanced ovarian cancers(24 epithelial ovarian cancers, 2 Brenner tumors, 2 malignant mixed miillerian tumors, 2 granulosa cell tumors, 1 struma ovarii, 1 Krukenberg tumor). All patients had underwent staging laparotomy, and postoperative adjuvant chemotherapy with platinum-based combination chemotherapy. PCR was performed using tissues preserved in liquid nitrogen at the time of debulking operation. Overexpression of HER-2/neu oncogene was defined as being equal to or greater than 1.5 a.u. We analyzed whether the HER-2/neu overexpression correlated with chemoresponsiveness and 5-year survival rate(5-YSR). Result: HER-2/neu oncogene amplification was present in all of the ovarian cancers(32/32). Significant overexpression[gene copy number(GCN) ≥1.5 a.u.] was present in 13 of 32 ovarian cancers(41%) and 12 of 24 epithelial ovarian cancers (50%). The clinical response rate to chemotherapy in high copy group(GCN ≥ 1.5 a.u.) was 67%(8/12) and that of low copy group(GCN $lt;1.5 a.u.) was 92%(11/12)(p$gt;0.05). Pathologic response rate to chemotherapy was 0%(0/5) and 50%(3/6), respectively(p$gt;0.05). 5-YSR was 8% in high copy group and 25% in low copy group, but this difference was not statistically significant(p=7). Conclusion: HER-2/neu overexpression might be a poor prognostic factor, but this difference was not definitely elucidated by statistical analysis in this study. Larger scaled prospective randomized study is needed to define the prognostic significance of the HER-2/neu overexpression in ovarian cancer.